If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
59
results.
Updated on
04/12/2025 [06:45:00]
Absstract of: EP4656205A1
Provided is a method for treating canine B-cell lymphoma that is more effective than conventional methods. The method for treating canine B-cell lymphoma includes administering an anti-canine CD20 monoclonal antibody in combination with a chemotherapeutic agent, simultaneously or sequentially. The chemotherapeutic agent is one or more of vincristine, cyclophosphamide, prednisolone, and doxorubicin. The monoclonal antibody against canine CD20 and the chemotherapeutic agent are administered in combination, simultaneously or sequentially.
Absstract of: NZ748650A
The application provides methods for treating Hodgkin lymphoma or non Hodgkin lymphoma in a subject comprising nivolumab and brentuximab vedotin administered according to a dosage schedule, wherein the subject is to be administered: (i) brentuximab vedotin at a dose of about 1.8 mg/kg once every three weeks on day 1 of a first 21-day cycle; (ii) nivolumab at a dose of about 3 mg/kg on day 8 of the first 21-day cycle; and wherein a combination of brentuximab vedotin and nivolumab is to be administered on day 1 of each of a second 21-day cycle, a third 21-day cycle; and a fourth 21-day cycle, wherein the second 21-day cycle, the third 21-day cycle, and the fourth 21-day cycle follow in succession after the first 21-day cycle.
Absstract of: NZ787952A
Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy for treating mantle cell lymphoma (MCL) or B cell acute lymphoblastic leukemia (ALL) in a subject in need thereof. The disclosure provides use of a therapeutically effective amount of comprising autologous T cells expressing an anti-CD19 chimeric antigen receptor (CAR) in the manufacture of a medicament for treating mantle cell lymphoma (MCL) or B cell acute lymphoblastic leukemia (ALL) in a subject in need thereof, wherein the anti-CD19 CAR comprises an anti-CD19 single-chain variable fragment (scFv) comprising the heavy chain and light chain variable regions of FMC63, a CD28 intracellular signaling region, and CD3-zeta signaling domain.
Absstract of: US2025360103A1
The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4;14) multiple myeloma, by administrating to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.
Absstract of: WO2025242806A1
The present invention relates to a method for predicting a response of a patient with diffuse large B-cell lymphoma (DLBCL) to anti-IL-1β therapy. This comprises detecting a mutation in the IRF2BP2 gene and/or a lack of IRF2BP2 protein expression of the patient's DLBCL cells in a sample derived from the patient. In addition, the invention relates to the use of such detection for predicting a response of the patient to IL-1β therapy and a corresponding PCR kit.
Absstract of: US2025361227A1
The invention relates to inhibitors of EWS-FLI1, pharmaceutical compositions containing the inhibitors, and methods of treating cancer, including Ewing sarcoma, leukemia, diffuse large B-cell lymphoma (DLBCL), and prostate cancer, comprising the administration of the inhibitors and pharmaceutical compositions thereof.
Absstract of: WO2025242013A1
Disclosed in the present invention are a tricyclic BCL6 degradation agent and the use thereof. The tricyclic compound provided by the present invention or a pharmaceutically acceptable salt and solvate thereof has a novel structure and exhibits an excellent degradation effect on BCL6 protein. Therefore, the compound provided by the present invention or a composition containing the compound provided by the present invention exhibits a promising potential for development as drugs for treating diseases that can be treated or relieved by means of degrading the BCL6 protein, e.g., cancers such as Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, NK/T cell non-Hodgkin lymphoma, or diffuse large B-cell lymphoma.
Absstract of: WO2025242012A1
Disclosed are protein-targeting degradation chimeras and the use thereof. The protein-targeting degradation chimeras have a new chemical structure, exhibit a great degradation effect on the BCL6 protein, can be used for preparing BCL6 degrader drugs, and has the potential to be developed into a drug for treating diseases that can be treated or alleviated by means of the degradation of the BCL6 protein. The diseases that can be treated or alleviated by means of the degradation of the BCL6 protein comprise cancers such as Hodgkin lymphoma, B-cell-derived non-Hodgkin lymphoma, T-cell-derived non-Hodgkin lymphoma, NK/T-cell-derived non-Hodgkin lymphoma and diffuse large B-cell lymphoma.
Absstract of: WO2025244832A1
The invention provides novel aminoguanidine compounds, pharmaceutical compositions and therapeutic uses thereof for treating various types of cancer (e.g., brain cancer, breast cancer, pancreatic cancer, renal cancer, lung cancer, leukemias, and lymphomas) and neurological disorders (e.g., Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis), and related diseases and conditions.
Absstract of: WO2025245434A1
Aspects of the disclosure provides composition and methods for treating a subject having MDS, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).
Absstract of: US2025360126A1
Compositions and methods are provided for reducing NPM1 glutamate-glutamylation and for treating cancers characterized by overexpression of TTLL4 and/or expression of a mutant NPM1.
Absstract of: WO2025244973A1
The present disclosure provides methods for treating multiple myeloma. In certain embodiments, the present methods comprise administering to a subject in need thereof bispecific antibodies or antigen-binding fragments thereof that bind to BCMA and CD3. In certain embodiments, the bispecific BCMAxCD3 antibodies are administered subcutaneously to the subject in need thereof. In certain embodiments, the subject has been previously treated with BCMA-CAR-T cell therapy.
Absstract of: WO2025243241A1
Embodiments of the present invention relate to methods of treating multiple myeloma in a subject in need thereof comprising administering to the subject a BCMAxCD3 bispecific antibody on a novel dosing schedule.
Absstract of: WO2025242909A1
The present invention relates to an antibody-radionuclide conjugate comprising a) an antibody or antigen-binding fragment thereof specifically binding to CD30; and b) terbium-161, as well as to a pharmaceutical composition comprising the conjugate of the invention as well as at least one pharmaceutically acceptable carrier. The present invention further relates to a kit of parts comprising a) an antibody or antigen-binding fragment thereof specifically binding to CD30; and b) terbium-161, wherein said antibody or antigen-binding fragment thereof is capable of binding terbium-161. The present invention further encompasses therapeutic uses of the provided conjugates. Accordingly, the antibody-radionuclide conjugates of the present invention are particularly useful in the treatment of cancer, in particular lymphoma.
Absstract of: US2025362298A1
Methods of monitoring progression of multiple myeloma or plasmacytoma, particularly relapsed or refractory multiple myeloma, are described. Also described are methods of treating or determining response to a treatment for multiple myeloma or plasmacytoma in a subject.
Absstract of: AU2024258228A1
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Absstract of: AU2024283865A1
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Absstract of: EP4653445A1
Provided is compound A or a pharmaceutically acceptable salt thereof in a crystalline form. The structure of compound A is represented by formula (I) below. Studies have shown that a crystalline form A-1 of the free base of compound A, crystalline form B of a hydrochloride salt of compound A and crystalline form C of a benzenesulfonate salt of compound A have certain physical stability and chemical stability. The compound A or the pharmaceutically acceptable salt thereof in a crystalline form can significantly inhibit the proliferation of various cells of tumors such as breast cancer, colorectal cancer, ovarian cancer, melanoma, liver cancer, lung cancer and acute myeloid leukemia; and also has a good inhibitory effect on palbociclib-resistant (including primary drug resistance and acquired drug resistance) breast cancer and liver cancer. Therefore, the compound A or the pharmaceutically acceptable salt thereof in a crystalline form has good clinical application prospects in the treatment of advanced malignant tumors, and provides a new drug choice for the treatment of CDK4/6 inhibitor-resistant tumors.
Absstract of: EP4653456A2
The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells.
Absstract of: AU2025259981A1
The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in methods for the treatment of acute myeloid leukemia (AML). The combination therapies 5 include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof. 10 15 20 25 The invention relates to combination therapies, particularly combination therapies for the treatment of myeloid malignancy. The combination therapies are particularly useful in 5 methods for the treatment of acute myeloid leukemia (AML). The combination therapies include an antibody or antigen binding fragment thereof that binds to CD70 and a BCL-2 inhibitor, preferably venetoclax or a pharmaceutically acceptable salt thereof. ct c t
Absstract of: US2025353854A1
Disclosed herein are heterocyclic compounds that inhibit the binding of menin and MLL or MLL fusion proteins. Also described are specific covalent inhibitors of a menin or menin-MLL interaction. Also disclosed are pharmaceutical compositions that include the compounds described herein. Methods of using the menin or menin-MLL irreversible inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, leukemia and other diseases or conditions dependent on menin or menin-MLL interaction.
Absstract of: US2025354218A1
The present technology relates to methods for predicting the risk of acute myeloid leukemia (AML) in a subject prior to the onset of AML symptoms, and whether such a subject will benefit from treatment with an AML therapy. The methods disclosed herein are based on detecting the presence of mutations in the nucleic acid sequences of IDH1/2, TP53, DNMT3A, TET2, and spliceosome genes. Kits for use in practicing the methods are also provided.
Absstract of: WO2025236094A1
Identification, Design and Validation of Public Neoantigens and Tumor-associated Antigen vaccines for the Prevention and Treatment of Down Syndrome-associated Leukemia.
Absstract of: WO2025237908A1
The present invention relates to the field of the treatment of cancer. In this study, the inventors found that VDAC2 is heterogeneously expressed in MM cells. VDAC2 protein expression correlated with BAK but not with BAX protein levels. Transient silencing of VDAC2, but not VDAC1 or VDAC3, sensitized MM cells to intrinsic mitochondrial apoptosis signals, alongside with the induction of pre-activated BAK and the increase of global, MCL1 and BCL2 mitochondrial priming. They also found a that a VDAC2 compound, efesevin recapitulated the sensitization effect of VDAC2 knock-down on BH3 mimetics apoptotic response. This novel VDAC2 modulator sensitized MM cells to BH3 mimetics targeting MCL1 (S63845) or BCL2 (Venetoclax) without modifying BAK or BAX protein expression. The efficiency of the VDAC2 modulator was directly correlated with the levels of VDAC2 protein. To better understand the VDAC2/BAK interplay, The inventors generated VDAC2 KO myeloma cells. VDAC2 KO cells exhibited an important decrease of BAK protein expression while BAX remained unchanged. Accordingly, VDAC2 KO cells completely lost their mitochondrial priming. Interestingly, they also found that BAK KO myeloma cells displayed decreased levels of VDAC2. The reciprocal regulation between VDAC2 and BAK was dependent on both the proteasome and lysosome degradation pathways. Thus, the present invention relates to a combination of a VDAC2 modulator and a BH3- mimetics compound for use in the treatment of a cancer in a s
Nº publicación: AU2024243824A1 20/11/2025
Applicant:
HAEMALOGIX LTD
HAEMALOGIX LTD
Absstract of: AU2024243824A1
The present disclosure relates to combination dosing regimen comprising an anti-KMA antibody, an IMiD/CELMoD and a steroid. Such combinations may be used for the treatment of multiple myeloma.
BOPI
Electronic site
